Pulse Journal Club Active Debates Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Home Explore Journal Club Trending

⌘+K

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia | Synapse

April 18, 2024Open Access

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Key Points

Key points are not available for this paper at this time.

Abstract

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Phely et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6e8afb6db643587663acf https://doi.org/https://doi.org/10.1001/jamaoncol.2024.0473

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia2018 · 5,641 citations
2CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome2023 · 234 citations
3KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study2021 · 769 citations
4Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy2021 · 77 citations
5Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)2018 · 52 citations